Does anyone have an opinion on or experience with Mayne's track record on reliability of their forward looking statements? If they say generic sales will improve, should we take it at face value and rely on it?
News: MYX Mayne Pharma Expects Q4 To Be Stronger Driven By Rebound In Generic Products, page-2
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.65 |
Change
-0.130(2.72%) |
Mkt cap ! $395.5M | |||
| Open | High | Low | Value | Volume |
| $4.72 | $4.76 | $4.56 | $825.4K | 176.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1960 | $4.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.68 | 123 | 1 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| MYX (ASX) Chart |